We identified 296 patients with T1/T2 N0 prostate adenocarcinoma who underwent RP. Median age was 60 years with a median followup of 2.3 years. A total of 59% (nZ177) of patients had Gleason 7 disease and 54% (nZ154) had T1 disease. In addition, 40.8% (nZ121) of patients had biochemical failure following RP. After adjusting for clinical covariates, 4 genes were associated with differences in biochemical failure (Table 1). Specifically, increased RNA expression of E2F3 (hazard ratio [HR] 1.11, P<.001), CTNNB1 (HR 1.49, PZ.002), and AR (HR 1.21, P<.001) were seen in patients who experienced biochemical failure. Expression of TP53 (HR 0.75, p<.001) and Gleason 7 disease (HR 0.62 vs Gleason 8-10, P<.001) were associated with decreased likelihood of biochemical failure. Clustering by pathologic T stage accounted for 10% of variance in biochemical failure indicating that the 4 genes add important information to the prediction of biochemical recurrence. Conclusion: Genomic data augments pretreatment clinical data as well as pathologic staging data in the stratification of patients at risk for biochemical failure following RP. RNA expression of E2F3, CTNNB1, AR, and TP53 is associated with differences in biochemical failure following RP. Clinically, these genes could aid in identifying patients who may benefit from more regionally directed pelvic and prostate radiation therapy. Further studies of the relationship between these genes and the development of prostate cancer could aid in future targeted therapies.
research, share research database, jointly publish, etc. The e-learning app links to free leading online learning platforms, enabling space-time flexible education/training. Conclusion: The use of ICTs to enable space-time flexible global health collaborations in radiation oncology can have a major impact right away. Today, people do not have to travel, with valuable time lost in transit, in order to participate in global health collaborations. Instead any time they can afford can be pooled/coordinated via the integrated platform for remote participation powered by ICTs. The emerging consensus is that the use of ICTs to catalyze global health collaborations in radiation oncology should be scaled-up, given the demonstrated potential in efforts that can save many lives and develop a new generation of global health leaders in radiation oncology.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.